Videos

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

Aparna Parikh, MD, MS, talks about the MD Anderson INTERCEPT program, which is studying the relationship between ctDNA and recurrence in colorectal cancer.

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

Following their review of data from MajesTEC-1, panelists consider how they manage patients with cytokine release syndrome in the real-world setting.

Daniel H. Ahn, DO, discusses the CIRCULATE-Japan trial, which is studying how ctDNA can be used to guide adjuvant therapy in colorectal cancer.

Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).

Results of a survey from the National Comprehensive Cancer Network indicate that almost all responding institutions are impacted by the carboplatin shortage.

Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.

Experienced clinicians share their perspectives on maintenance therapy for patients with NDMM.

In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.

Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

The expert panel discuss emerging data on menin inhibitors in the second-line treatment of AML, including an overview of the KOMET-001 trial evaluating ziftomenib.

Experts on acute myeloid leukemia share clinical insights on first-line combination therapies, including the potential role of menin inhibitors in this setting.

Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.

Discussion centered around the role of allogeneic transplants in the treatment of MDS, MPN, and AML, focusing on the transplant process, eligibility criteria, patient selection, and post-transplant monitoring.

Subject-matter experts highlight unmet needs in AML treatment, investigational therapies, and emerging targets showcased in recent studies.

Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.

Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.

Ajay Nooka, MD, MPH, FACP leads a survey of the MAIA study, including a sub-group analysis of the MAIA study in frail patients, as well as findings from the MagnetisMM-6 study.

Jonathan Kaufman, MD describes a second patient case featuring a 76-year-old female diagnosed with transplant-ineligible NDMM.

According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.

Joshua Sabari, MD, and Misako Nagasaka, MD, reflect on clinical trial data and experience with mobocertinib in patients with EGFR Exon20+ non–small cell lung cancer.

A Q&A session with the expert panel.

Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.

Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.

A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.